The Regulator

FDA is requiring every GLP-1 drug, from Ozempic and Wegovy to Zepbound and the newly approved Foundayo, to add a warning for a rare form of sudden vision loss. The Food and Drug Administration (FDA) issued the Drug Safety Communication Monday, November 9, covering non-arteritic anterior ischemic optic neuropathy (NAION), a stroke of the optic nerve. Who it hits: every holder of a GLP-1 receptor agonist application, including semaglutide, tirzepatide, liraglutide, dulaglutide and orforglipron makers, plus the prescribers and patients on them. So what: FDA’s own pooled analysis of 126 randomized trials (134,253 patients) found 15 probable NAION events, 10 on GLP-1 drugs, 5 on placebo and none on other glucose-lowering drugs, or 6.4 versus 3.8 cases per 100,000 person-years. FDA gives no hazard ratio for that analysis and calls the finding a “potential increased risk.” In its Sentinel claims cohort, the risk was higher versus DPP-4 inhibitors (hazard ratio 1.43, 95% confidence interval 1.02 to 2.01) but not statistically different versus SGLT-2 inhibitors (1.19, 0.91 to 1.54). The language goes in Warnings and Precautions, not a boxed warning. Clinicians are told to refer patients with sudden painless vision loss in one eye to an ophthalmologist and to consider stopping the drug if NAION is confirmed, unless benefits clearly outweigh the risk. Confidence: High on every figure, which comes from the FDA page; the FDA page sets no deadline for manufacturers to file the label changes, so timing is unknown. Source: FDA Drug Safety Communication, November 9, 2026.

FDA proposes moving cancer-drug companion tests for HER2, PD-L1, ALK and more from the hardest approval pathway to a faster one. The proposed order, scheduled for Federal Register publication Thursday, November 12, would reclassify immunohistochemistry (IHC) test systems used with a corresponding approved oncology drug from class III (premarket approval) to class II (special controls, with a 510(k) premarket notification). Who it hits: makers of IHC diagnostics and the oncology drugs paired with them. So what: the proposal covers 12 product codes, and FDA says it has approved 22 original premarket approvals and about 270 supplements across them. Tests already approved could stay on the market under their existing approvals. FDA is responding to a January 7, 2026 petition from Ventana. Comments are due January 11, 2027. Confidence: Med; the effective-date section of the order was not independently confirmed, and FDA gives no dollar estimate. Source: Federal Register, document 2026-23005 (Docket FDA-2026-N-12508).

FDA asks drugmakers how to hand it patient-level real-world data, a snag that can stall applications built on real-world evidence. The request for information, also scheduled for publication November 12, is not a rule. Who it hits: drug and biologic sponsors, data holders, electronic health data vendors and academic medical centers. So what: FDA says sponsors often do not own the data, it cannot sign data-use agreements that conflict with its records and public-records duties, and it does not accept links to external databases, so today’s workaround is a pre-investigational new drug meeting or a drug master file. It asks four questions on data-use agreements, receiving and keeping the data, and working with outside parties. Comments are due January 11, 2027. Confidence: High; the language is from the notice. Source: Federal Register, document 2026-22996 (Docket FDA-2026-N-10742).

FDA’s draft guidance on first-in-human cancer trials opens for comment, also due January 11, 2027. The notice, scheduled for November 12 publication under Docket FDA-2026-D-13432, gives recommendations to sponsors and investigators designing early-phase protocols for solid tumors, including first-in-human studies. Who it hits: cancer drug developers and the trial sites that run their first studies. So what: this is draft guidance, which does not bind FDA or sponsors, but the comment window is the chance to change the final version. Confidence: Med; we read the notice’s abstract and dates, not the full draft guidance. Source: Federal Register, document 2026-22970.

Two New Mexico and Texas tribes get larger Indian Health Service referral areas, effective on publication Thursday. The Indian Health Service (IHS) is expanding the Purchased/Referred Care Delivery Area (PRCDA) for the Ysleta Del Sur Pueblo to add Doña Ana County, New Mexico, so it covers that county plus El Paso and Hudspeth Counties, Texas. It is also expanding the Kewa Pueblo’s area to add Bernalillo County, so it covers Bernalillo, Sandoval and Santa Fe Counties, New Mexico. Who it hits: tribal members living in the added counties and the outside clinics and hospitals that treat them. So what: a delivery-area residence is what makes a tribal member eligible for care paid for through IHS referrals outside IHS facilities, so these notices widen who can be sent out. Neither notice states a dollar figure. Confidence: High on the boundaries and effective dates, which come from the notices. Sources: Federal Register, Ysleta Del Sur Pueblo notice 2026-23038, Federal Register, Kewa Pueblo notice 2026-23036.

Quiet note: we found no same-day Justice Department or HHS inspector general health care enforcement announcement we could confirm at press time, so none is included.